APLS · As filed with the SEC
Apellis Pharmaceuticals cash flow statement, by fiscal year
The statement as Apellis Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net income/(loss) | 22,388,000 | (197,878,000) | (528,628,000) | (652,172,000) |
| Adjustments to reconcile net income/(loss) to net cash used in operating activities: | ||||
| Share-based compensation expense | 104,003,000 | 114,128,000 | 105,945,000 | 91,085,000 |
| Loss on conversion of debt | — | — | — | 32,890,000 |
| Loss on extinguishment of development liability | — | 1,949,000 | — | — |
| Loss on disposal of fixed assets | — | — | 120,000 | — |
| Forfeiture of accrued interest in exchange of convertible notes | — | — | — | 1,287,000 |
| Depreciation expense | 1,558,000 | 1,797,000 | 1,784,000 | 1,552,000 |
| Amortization of discounts for credit facility | — | 1,250,000 | — | — |
| Amortization of discounts for convertible notes | — | 309,000 | — | — |
| Amortization of right of use assets | — | — | (80,000) | (65,000) |
| Amortization Of Discounts For Convertible Notes Net Of Financing Costs | — | — | 297,000 | 459,000 |
| Amortization of Discounts for Credit Facility and Convertible Notes | 2,496,000 | — | — | — |
| Accretion of discount to development liability | — | 8,936,000 | 25,996,000 | 26,917,000 |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | (101,279,000) | (58,484,000) | (198,715,000) | 2,375,000 |
| Inventory | (15,267,000) | (10,755,000) | (60,647,000) | (69,397,000) |
| Prepaid assets | — | 20,420,000 | (1,870,000) | (11,479,000) |
| Other current assets | — | 10,793,000 | 14,243,000 | 32,936,000 |
| Prepaid and other current assets | (8,087,000) | — | — | — |
| Other assets | (4,061,000) | 705,000 | 11,700,000 | 17,490,000 |
| Right-of-use assets and lease liabilities | (34,000) | (277,000) | — | — |
| Accounts payable | 18,223,000 | 1,089,000 | 170,000 | 18,689,000 |
| Accrued expenses and other liabilities | 25,387,000 | 18,152,000 | 34,950,000 | (6,312,000) |
| Net cash provided by/(used in) operating activities | 45,327,000 | (87,866,000) | (594,735,000) | (513,745,000) |
| Investing Activities | ||||
| Purchase of property and equipment | (313,000) | (403,000) | (773,000) | (1,524,000) |
| Proceeds from sale of fixed assets | — | — | 99,000 | — |
| Purchase of available-for-sale securities | — | — | — | (331,863,000) |
| Proceeds from maturity of available-for-sale securities | — | — | — | 393,280,000 |
| Net cash used in investing activities | (313,000) | (403,000) | (674,000) | 59,893,000 |
| Financing Activities | ||||
| Proceeds from credit facility | — | 365,454,000 | — | — |
| Payment of issuance cost for credit facility | — | (7,214,000) | — | — |
| Repayment of development liability | — | (326,533,000) | — | — |
| Proceeds from settlement of capped call | — | 98,763,000 | — | — |
| Proceeds from issuance of common stock, net of issuance costs | — | — | — | 380,120,000 |
| Proceeds from issuance of common stock, pre-funded warrant offering, net of issuance costs | — | — | 384,387,000 | — |
| Payments for development liability | — | — | (55,500,000) | (34,500,000) |
| Proceeds from exercise of stock options and warrants | — | — | — | 21,483,000 |
| Proceeds from exercise of stock options | 5,545,000 | 14,316,000 | 71,274,000 | — |
| Proceeds from issuance of common stock under employee share purchase plan | 3,350,000 | 4,512,000 | 5,378,000 | 4,238,000 |
| Payments of employee tax withholding related to equity-based compensation | (11,000) | (57,000) | (11,040,000) | (5,682,000) |
| Net cash provided by financing activities | 8,884,000 | 149,241,000 | 394,499,000 | 365,659,000 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,250,000 | (659,000) | 135,000 | (488,000) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 55,148,000 | 60,313,000 | (200,775,000) | (88,681,000) |
| Cash, cash equivalents and restricted cash at beginning of period | 412,612,000 | 352,299,000 | 553,074,000 | 641,755,000 |
| Cash, cash equivalents and restricted cash at end of period | 467,760,000 | 412,612,000 | 352,299,000 | 553,074,000 |
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for interest | 41,233,000 | 29,368,000 | 3,286,000 | 5,003,000 |
| Cash paid for income taxes | — | — | — | 4,915,000 |
| Cash paid for income taxes | — | 1,649,000 | — | — |
| Proceeds from income tax refunds net of income taxes paid | — | — | 1,759,000 | — |
| Convertible Notes exchanged for common stock | — | — | — | 98,086,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.